TheraVac Biologics has announced a strategic partnership with Perceiv AI to optimize the clinical trial of its lead vaccine candidate, TV-301, for patients with mild cognitive impairment due to Alzheimer's disease. The collaboration will leverage Perceiv AI's multimodal Foresight™ platform and AD-Px™ digital prognostic biomarker engine to improve patient selection and trial outcomes.
This partnership aims to address the challenges of patient selection in Alzheimer's disease clinical trials, where identifying individuals most likely to benefit from treatment is crucial. Alzheimer's disease affects millions worldwide, with the Alzheimer's Association estimating that 6.9 million Americans aged 65 and older are living with the disease in 2024. The current treatment landscape is limited, highlighting the urgent need for innovative therapies.
AI-Driven Patient Selection
Perceiv AI's AD-Px™ engine is designed to forecast disease progression in age-related diseases like Alzheimer's. By integrating this technology into the clinical trial design, TheraVac intends to identify and enroll patients who are most likely to respond to TV-301. This tailored approach is expected to increase the efficiency and success rate of the trial.
Laurent Balenci, PhD, Co-founder and COO of TheraVac, stated, "By integrating Perceiv AI's prognostic capabilities in our clinical trial design, we will significantly reduce the time and expense of conducting clinical trials, while maximizing the outcomes for patients in need."
TV-301: A Novel Immunotherapy Approach
TV-301 is a novel active immunotherapy being developed by TheraVac Biologics that targets protein misfolding and chronic inflammation, key hallmarks of neurodegenerative and autoimmune diseases. Preclinical studies have demonstrated the vaccine's safety, immune response, and efficacy in animal models. TheraVac anticipates that TV-301 will offer a convenient, safe, and efficacious addition to the current standard of care for neurodegenerative diseases.
The Role of Perceiv AI
Perceiv AI's Foresight™ platform offers a multimodal approach to forecasting disease progression. Christian Dansereau, PhD, CEO of Perceiv AI, noted, "Our collaboration with TheraVac Biologics represents a great step towards a novel and digital, AI-powered holistic approach to optimize patient selection and successful clinical outcomes in the fight against brain diseases."
By using AI to refine patient selection, TheraVac and Perceiv AI hope to accelerate the development of effective treatments for Alzheimer's disease and other neurodegenerative conditions.
